TAS-102 vs. placebo with best supportive care in refractory patients with met colorectal cancer

Speaker: Josep Tabernero

J.Tabernero goes through the design and results of the global RECOURSE trial in metastatic colorectal cancer refractory to standard therapies, highlighting the improved overall survival in such advanced setting. The current results show promise for this patient population.

Discussion Points

In this video, Josep Tabernero discusses:

  • What is TAS-102 and how it works? 
  • What are preclinical and early clinical findings with TAS-102?
  • Design and results of RECOURSE study in patients with metastatic colorectal cancer refractory to standard therapies.